Proteasome inhibitors such as bortezomib and carfilzomib possess yet another advantage over specific Gli inhibitors, as they are FDA-approved drugs in the treatment of multiple myeloma, which greatly simplifies the process for new therapy approval. Here, GLI1 is linked to plasma cell myeloma.